-
This “DRUG REGISTRATION GUIDANCE DOCUMENT (DRGD)” will serve as the reference guide for the registration process including quality control, inspection & licensing and post-registration activities of medicinal products.
- This DRGD shall be read in conjunction with the current laws and regulations together with other relevant legislations, where applicable, governing pharmaceutical and natural products for human use in Malaysia, which include but are not limited to the following:
- Sale of Drugs Act 1952;
- Control of Drugs and Cosmetics Regulations 1984;
- Dangerous Drugs Act 1952;
- Poisons Act 1952;
- Medicines (Advertisement & Sale) Act 1956;
- Wildlife Conservation Act 2010 (Laws of Malaysia Act 716); and
- International Trade in Endangered Species Act 2008 (Act 686).
-
The written laws shall take precedence over this guidance document in any event of discrepancy.
This guidance document is issued by the Director of Pharmaceutical Services under Regulation 29Control of Drugs and Cosmetics Regulations 1984.
DRGD Appendices
Document Name | Updated |
---|---|
Drug Registration Guidance Document (DRGD), 3rd Edition, Eighth Revision July 2024 (Main body) | July 2024 |
Appendix 1 : Food Drug Interphase (FDI) Products | July 2024 |
Appendix 2 : Medical Device-Drug-Cosmetic Interphase (MDDCI) and Combination Products | July 2024 |
Appendix 3 : Guideline on Registration of New Drug Products | July 2024 |
Appendix 4 : Guideline on Registration of Biologics | July 2024 |
Appendix 5 : Guideline on Registration of Generics | July 2024 |
Appendix 6 : Guideline on Registration of Health Supplements | July 2024 |
Appendix 7 : Guideline on Registration of Natural Products | July 2024 |
Appendix 7A : Homeopathic Products | July 2024 |
Appendix 7B : Guideline on Natural Products with Modern Claim | July 2024 |
Appendix 7C : Guideline on Natural Products with Therapeutic Claim | July 2024 |
Appendix 8 : Supplementary Documentation (Particulars of Product Owner and Manufacturer) | July 2024 |
Appendix 9 : Fees | July 2024 |
Appendix 10 : Data Exclusivity | July 2024 |
Appendix 11 : Regulatory Control of Active Pharmaceutical Ingredients (APIs) | July 2024 |
Appendix 12 : Priority Review | July 2024 |
Appendix 13 : Designation and Registration of Orphan Drugs | July 2024 |
Appendix 14 : Evaluation Routes | July 2024 |
Appendix 15 : Requirements for Full Evaluation and Abridged Evaluation | July 2024 |
Appendix 16 : Bioequivalence (BE) Requirements | July 2024 |
Appendix 17 : Product Names Not Permitted to Be Registered | July 2024 |
Appendix 18 : List of Permitted, Prohibited and Restricted Substances | July 2024 |
Appendix 19 : General Labelling Requirements | July 2024 |
Appendix 19A : Prohibited Visual/ Graphics/Statements on Label | July 2024 |
Appendix 20 : Specific Labelling Requirements | July 2024 |
Appendix 21 : Special Conditions for Registration of a Particular Product or Group of Products | July 2024 |
Appendix 22 : Educational Materials | July 2024 |
Appendix 23 : Patient Dispensing Pack for Pharmaceutical Products | July 2024 |
Appendix 24 : Appeal | July 2024 |
Appendix 25 : Guideline for the Submission of Protocol of Analysis (POA) | July 2024 |
Appendix 26 : Guideline for the Submission of Analytical Method Validation (AMV) Documents | July 2024 |
Appendix 27 : Inspection | July 2024 |
Appendix 28 : Licensing | July 2024 |
Appendix 29 : Certificate | July 2024 |
Appendix 30 : Change of Manufacturing Sites (COS) | July 2024 |
Appendix 31 : Change of Product Registration Holder (COH) | July 2024 |
Appendix 32 : Explanatory Notes for Repackers | July 2024 |
Appendix 33 : Guideline on Safety Data Requirements for Complementary Medicine Products | July 2024 |
List of DRGD Updates
DRGD Table of Contents
2. Product Definition
3. Product Classification (Appendix 1 to 7)
4. Exemptions for Products Not Registered With the Authority
5. Application Procedures
5.1 Who Shall Apply for Product Registration
5.2 Responsibilities of the Applicant
5.3 How To Apply
5.4 Fees (Appendix 9)
6.1 Category of Product
6.2 Data Exclusivity (Appendix 10)
6.3 Type of Application
6.3.1 Application for Priority Review (Appendix 12)
6.3.2 Registration of Combination Pack (Combo Pack)
6.3.3 Registration of For Export Only (FEO) Product
6.3.4 Designation and Registration of Orphan Medicines (Appendix 13)
6.3.5 Variants
6.3.6 Multiple Applications
6.3.7 Second or Third Source
6.4 Evaluation routes (Appendix 14)
7. Regulatory Requirements
7.1 Requirements for Full Evaluation and Abridged Evaluation (Appendix 15)
7.2 Bioequivalence (BE) Requirements (Appendix 16)
7.3 Product Name (Appendix 17)
7.4 Ingredients (Appendix 18)
7.5 Indications
7.6 Labelling Requirements (Appendix 19, 19A, 20)
7.7 Special Conditions for Registration of a Particular Product or Group of Products (Appendix 21)
7.8 Educational Materials (Appendix 22)
7.9 Packaging
7.9.1 Shrink wrapping
7.9.2 Starter Pack/ Patient Initiation Pack/ Dose Adjustment Pack
7.9.3 Patient Dispensing Pack (Appendix 23)
7.10 Proposed Package Insert
7.11 Consumer Medication Information Leaflet (RiMUP)
7.12 Product Authentication
7.13 Language
7.14 Halal Logo
7.15 Directives
8. SUBMISSION OF APPLICATION
9. SCREENING OF APPLICATION
9.1 Satisfactory
9.2 Non-Satisfactory
10. EVALUATION OF APPLICATION
10.1 Initiation of Review
10.2 Correspondence
10.3 Evaluation Timeline for Product Registration
11. REGULATORY OUTCOME
11.1 Decisions of the Authority
11.2 Product Registration Number
11.3 Certificate of Registration
11.4 Appeal Towards Decision of the Authority (Appendix 24)
13. GUIDELINE FOR THE SUBMISSION OF ANALYTICAL METHOD VALIDATION (AMV) DOCUMENTS (Appendix 26)
14. GUIDELINE FOR THE SUBMISSION OF PRODUCT SAMPLES FOR LABORATORY TESTING
14.1 Natural Products
14.2 Pharmaceutical Products (Upon NPRA request)
16. LICENSING (Appendix 28)
17. CERTIFICATE (Appendix 29)
19. WITHDRAWAL OF PRODUCT REGISTRATION
20. AMENDMENTS TO PARTICULARS OF A REGISTERED PRODUCT
20.1 Variation
20.1.1 Variation Application for Pharmaceutical Products
20.1.2 Variation Application for Health Supplement and Natural Products
20.1.3 Variation Application for Biological Products
20.2 Change of Manufacturing Site (COS) (Appendix 30)
20.3 Change of Product Registration Holder (COH) (Appendix 31)
20.4 New/ Additional Indication
20.5 Convenient Pack
21. POST-MARKETING ACTIVITIES
21.1 Pharmacovigilance
21.2 Product Quality Monitoring (PQM)
21.2.1 Product Quality Monitoring (PQM) Programme
21.2.2 Product Sampling
21.2.3 Product Testing
21.2.4 Monitoring of Label Compliance
21.2.5 Product Quality Reporting
21.2.6 Risk Communication on Information of Product Issues
21.2.7 Regulatory Action
21.2.8 Adulteration